Literature DB >> 24006238

Epigenetic mechanisms of neurodegeneration in Huntington's disease.

Junghee Lee1, Yu Jin Hwang, Ki Yoon Kim, Neil W Kowall, Hoon Ryu.   

Abstract

Huntington's disease (HD) is an incurable and fatal hereditary neurodegenerative disorder of mid-life onset characterized by chorea, emotional distress, and progressive cognitive decline. HD is caused by an expansion of CAG repeats coding for glutamine (Q) in exon 1 of the huntingtin gene. Recent studies suggest that epigenetic modifications may play a key role in HD pathogenesis. Alterations of the epigenetic "histone code" lead to chromatin remodeling and deregulation of neuronal gene transcription that are prominently linked to HD pathogenesis. Furthermore, specific noncoding RNAs and microRNAs are associated with neuronal damage in HD. In this review, we discuss how DNA methylation, post-translational modifications of histone, and noncoding RNA function are affected and involved in HD pathogenesis. In addition, we summarize the therapeutic effects of histone deacetylase inhibitors and DNA binding drugs on epigenetic modifications and neuropathological sequelae in HD. Our understanding of the role of these epigenetic mechanisms may lead to the identification of novel biological markers and new therapeutic targets to treat HD.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24006238      PMCID: PMC3805871          DOI: 10.1007/s13311-013-0206-5

Source DB:  PubMed          Journal:  Neurotherapeutics        ISSN: 1878-7479            Impact factor:   7.620


  122 in total

1.  p53 mediates cellular dysfunction and behavioral abnormalities in Huntington's disease.

Authors:  Byoung-Il Bae; Hong Xu; Shuichi Igarashi; Masahiro Fujimuro; Nishant Agrawal; Yoichi Taya; S Diane Hayward; Timothy H Moran; Craig Montell; Christopher A Ross; Solomon H Snyder; Akira Sawa
Journal:  Neuron       Date:  2005-07-07       Impact factor: 17.173

Review 2.  Striatal D2 receptors and LTD: yes, but not where you thought they were.

Authors:  Charles J Wilson
Journal:  Neuron       Date:  2006-05-04       Impact factor: 17.173

Review 3.  Emerging chemotherapeutic strategies for Huntington's disease.

Authors:  Hoon Ryu; Robert J Ferrante
Journal:  Expert Opin Emerg Drugs       Date:  2005-05       Impact factor: 4.191

4.  RNA interference improves motor and neuropathological abnormalities in a Huntington's disease mouse model.

Authors:  Scott Q Harper; Patrick D Staber; Xiaohua He; Steven L Eliason; Inês H Martins; Qinwen Mao; Linda Yang; Robert M Kotin; Henry L Paulson; Beverly L Davidson
Journal:  Proc Natl Acad Sci U S A       Date:  2005-04-05       Impact factor: 11.205

5.  Intrastriatal rAAV-mediated delivery of anti-huntingtin shRNAs induces partial reversal of disease progression in R6/1 Huntington's disease transgenic mice.

Authors:  Edgardo Rodriguez-Lebron; Eileen M Denovan-Wright; Kevin Nash; Alfred S Lewin; Ronald J Mandel
Journal:  Mol Ther       Date:  2005-10       Impact factor: 11.454

6.  Transcriptional therapy with the histone deacetylase inhibitor trichostatin A ameliorates experimental autoimmune encephalomyelitis.

Authors:  Sandra Camelo; Antonio H Iglesias; Daehee Hwang; Brice Due; Hoon Ryu; Karen Smith; Steven G Gray; Jaime Imitola; German Duran; Basel Assaf; Brett Langley; Samia J Khoury; George Stephanopoulos; Umberto De Girolami; Rajiv R Ratan; Robert J Ferrante; Fernando Dangond
Journal:  J Neuroimmunol       Date:  2005-07       Impact factor: 3.478

7.  Differential subnuclear localization and replication timing of histone H3 lysine 9 methylation states.

Authors:  Rong Wu; Anna V Terry; Prim B Singh; David M Gilbert
Journal:  Mol Biol Cell       Date:  2005-03-23       Impact factor: 4.138

Review 8.  The therapeutic role of creatine in Huntington's disease.

Authors:  Hoon Ryu; H Diana Rosas; Steven M Hersch; Robert J Ferrante
Journal:  Pharmacol Ther       Date:  2005-08-01       Impact factor: 12.310

9.  Neuroprotective effects of phenylbutyrate in the N171-82Q transgenic mouse model of Huntington's disease.

Authors:  Gabriella Gardian; Susan E Browne; Dong-Kug Choi; Peter Klivenyi; Jason Gregorio; James K Kubilus; Hoon Ryu; Brett Langley; Rajiv R Ratan; Robert J Ferrante; M Flint Beal
Journal:  J Biol Chem       Date:  2004-10-19       Impact factor: 5.157

10.  rAAV-mediated shRNA ameliorated neuropathology in Huntington disease model mouse.

Authors:  Yoko Machida; Takashi Okada; Masaru Kurosawa; Fumitaka Oyama; Keiya Ozawa; Nobuyuki Nukina
Journal:  Biochem Biophys Res Commun       Date:  2006-03-03       Impact factor: 3.575

View more
  30 in total

1.  Looking above but not beyond the genome for therapeutics in neurology and psychiatry: epigenetic proteins and RNAs find a new focus.

Authors:  Manuela Basso; Sama Sleiman; Rajiv R Ratan
Journal:  Neurotherapeutics       Date:  2013-10       Impact factor: 7.620

Review 2.  Epigenetic Regulation in Neurodegenerative Diseases.

Authors:  Amit Berson; Raffaella Nativio; Shelley L Berger; Nancy M Bonini
Journal:  Trends Neurosci       Date:  2018-06-07       Impact factor: 13.837

Review 3.  The Tiny Drosophila Melanogaster for the Biggest Answers in Huntington's Disease.

Authors:  Abraham Rosas-Arellano; Argel Estrada-Mondragón; Ricardo Piña; Carola A Mantellero; Maite A Castro
Journal:  Int J Mol Sci       Date:  2018-08-14       Impact factor: 5.923

4.  PRMT5- mediated symmetric arginine dimethylation is attenuated by mutant huntingtin and is impaired in Huntington's disease (HD).

Authors:  Tamara Ratovitski; Nicolas Arbez; Jacqueline C Stewart; Ekaterine Chighladze; Christopher A Ross
Journal:  Cell Cycle       Date:  2015       Impact factor: 4.534

5.  Factors influencing the clinical expression of intermediate CAG repeat length mutations of the Huntington's disease gene.

Authors:  Peter K Panegyres; Chen-Chun Shu; Huei-Yang Chen; Jane S Paulsen
Journal:  J Neurol       Date:  2014-11-08       Impact factor: 4.849

6.  Nucleosome Histone Tail Conformation and Dynamics: Impacts of Lysine Acetylation and a Nearby Minor Groove Benzo[a]pyrene-Derived Lesion.

Authors:  Iwen Fu; Yuqin Cai; Nicholas E Geacintov; Yingkai Zhang; Suse Broyde
Journal:  Biochemistry       Date:  2017-03-22       Impact factor: 3.162

Review 7.  Epigenetics of Aging and Alzheimer's Disease: Implications for Pharmacogenomics and Drug Response.

Authors:  Ramón Cacabelos; Clara Torrellas
Journal:  Int J Mol Sci       Date:  2015-12-21       Impact factor: 5.923

Review 8.  DNA methylation in Huntington's disease: Implications for transgenerational effects.

Authors:  Elizabeth A Thomas
Journal:  Neurosci Lett       Date:  2015-11-11       Impact factor: 3.046

9.  Protective effects of histone deacetylase inhibition by Scriptaid on brain injury in neonatal rat models of cerebral ischemia and hypoxia.

Authors:  Qingmei Meng; Guifeng Yang; Yu Yang; Fucheng Ding; Fengxian Hu
Journal:  Int J Clin Exp Pathol       Date:  2020-02-01

Review 10.  Epigenetic Changes and Its Intervention in Age-Related Neurodegenerative Diseases.

Authors:  Nuraqila Mohd Murshid; Faridah Aminullah Lubis; Suzana Makpol
Journal:  Cell Mol Neurobiol       Date:  2020-10-19       Impact factor: 5.046

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.